Capecitabine Added to Standard Treatment Given Before Surgery Helps to Eradicate Tumours in Patients With Early Breast Cancer

September 23, 2009

BERLIN, September 23 /PRNewswire/ –

– The Austrian Breast and Colorectal Cancer Study Group Present Data
Which Highlight Benefits of Adding capecitabine to epirubicin and docetaxel
in the Neoadjuvant Setting

Data from the ABCSG-24 study presented today at the joint 15th ECCO and
34th ESMO congress in Berlin, Germany, show that adding capecitabine
(Xeloda(R)) to anthracycline- and taxane-containing regimens prior to surgery
(neoadjuvant therapy) completely eradicated the tumour in 24% of women with
HER2-positive or HER2-negative early breast cancer. This is an impressive
finding since the proportion of women achieving total tumour eradication with
standard chemotherapy[*] for HER2-positive or HER2-negative early breast
cancer is less than 20% (range 6-18%).[1]

“These new data show that adding capecitabine to epirubicin and docetaxel
neoadjuvant regimens when treating women with early breast cancer, results in
increased efficacy compared to epirubicin and docetaxel alone. This new data
could lead to improvements in treatment for women with early stages of the
disease as the increased efficacy may result in prolonged overall survival,”
said Professor Günther Steger, Division of Oncology, Department of Internal
Medicine I, Medical University of Vienna, General Hospital Vienna, Vienna,

Despite recent advances, there is still an unmet need in the treatment
and management of early breast cancer with relapse occurring in approximately
30-50% of patients, depending on individual risk factors, even after
chemotherapy.[2] In addition to the ABCSG-24 study, several other studies of
neoadjuvant combination regimens that included capecitabine have shown
positive efficacy results.[3],[4],[5],[6],[7],[8],[9] The therapeutic success
in these studies was measured as complete pathological response (complete
disappearance of tumour cells in the breast and in the lymph nodes), which is
a strong predictor for long-term survival.[1], [10]

Breast cancer is the second most common cancer in the world and the most
common cancer among women.[11] There are 1.1 million new cases of female
breast cancer each year worldwide.[11]

Notes to editors:

Abstract: A randomized phase III study comparing epirubicin, docetaxel
and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant
treatment for early breast cancer. First results of ABCSG-24, a trial by the
Austrian Breast and Colorectal Cancer Study Group (ABCCSG).

Authors: G. G. Steger, R. Greil, R. Jakesz, A. Lang, B. Mlineritsch, E.
Melbinger-Zeinitzer, C. Marth, H. Samonigg, E. Kubista, M. Gnant Austrian
Breast and Colorectal Cancer Study Group; Medical University of Vienna,
Vienna, Austria; Paracelsus University Salzburg, Salzburg, Austria; Medical
University of Vienna, Vienna, Austria; Feldkirch Hospital, Feldkirch,
Austria; Wolfsberg Hospital, Wolfsberg, Austria; Medical University of
Innsbruck, Innsbruck, Austria; Medical University of Graz, Graz, Austria

Presentation: ORAL presentation, Wednesday 23 September 2009, 13.15-13.30
CET, joint 15th ECCO and 34th ESMO, Berlin, Germany.

About the study

The primary aim of the study was to evaluate the efficacy of capecitabine
added to epirubicin and docetaxel for six cycles (EDC) compared with six
cycles of epirubicin and docetaxel (ED) in terms of the achievable rate of
pathological complete responses (pCR) at the time of surgery in women with
early breast cancer.

Between November 2004 and November 2008, 536 patients with biopsy-proven
operable breast cancer who were scheduled to receive neoadjuvant treatment
were recruited to the study:

    - Cancers were of any clinical T-stage (except T4d), with or without
      nodal involvement and without distant disease

    - 236 patients enrolled for each group including a 5% drop out rate to
      give 510 eligible patients

    - Patients were stratified according to known risk factors and randomised
      to receive either six cycles of EDC every 21 days (E: 75 mg/m squared
      i.v. and D: 75 mg/msquared i.v. on day 1, C: 2 x 1000 mg/msquared/day
      for 14 days orally) or six cycles of ED (identical treatment regimen
      without C).

    Results to date show:

    - 24.0% pCR for the capecitabine containing treatment arm vs 16.0% pCR
      without capecitabine (p=0.02)

    - Toxicity of ED is increased with the addition of capecitabine, but side
      effects of the EDC regimen are well managed (94% of patients completing
      all six cycles of EDC compared with 96% completing six cycles for ED

ABCSG – A Global Player In Clinical Oncology

The Austrian Breast & Colorectal Cancer Study Group (ABCSG) is a
cooperative institution that was set up to conduct controlled clinical trials
in breast and colorectal cancer and to facilitate communication and the
dissemination of knowledge among scientists and others dedicated to the
cancer problem. Since its establishment in 1984, a total of more than 20.000
patients have been enrolled in ABCSG investigations. In certain patient risk
groups, ABCSG is currently recruiting up to 30 per cent of all Austrian
breast cancer patients to their clinical trials. The ultimate goal of the
ABCSG is to enhance the standard of cancer treatment in this country and
abroad by developing innovative approaches and testing increasingly more
effective therapeutic strategies. For more information visit:


[*] anthracycline plus cyclophosphamide or anthracycline plus a taxane

[1] Kaufmann M, von Minckwitz G, Smith R, et al: International expert
panel on the use of primary (preoperative) systemic treatment of operable
breast cancer: Review and recommendations. J Clin Oncol 2003;21:2600-2608

[2] Olivotto IA, Bajdik CD, Ravdin PM, et al. Population-based validation
of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol

[3] Lee KS, Ro J, Nam BH, et al. A randomized phase-III trial of
docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary
chemotherapy for patients with stage II/III breast cancer. Breast Cancer Res
Treat 2008;109:481-9.

[4] Berton-Rigaud D, Roché H, Penault-Llorca F, et al. Benefit of
neoadjuvant capecitabine + epirubicin + cyclophosphamide (CEX) vs 5-FU +
epirubicin + cyclophosphamide (FEC) for operable breast cancer followed by
adjuvant docetaxel. J Clin Oncol 2008;26(May 20 Suppl.):598.

[5] Wildiers H, Neven P, Christiaens M-R, et al. Multicenter phase II
study of neoadjuvant capecitabine and docetaxel plus or minus trastuzumab for
patients with locally advanced breast cancer: final analysis. Cancer Res
2009;69(Suppl. S):335S.

[6] Greil R, Moik M, Reitsamer R, et al. Neoadjuvant bevacizumab,
docetaxel and capecitabine combination therapy for HER2/neu-negative invasive
breast cancer: Efficacy and safety in a phase II pilot study. Eur J Surg
Oncol 2009 Feb 26. [Epub ahead of print].

[7] Bellet M, Muñoz M, Pelegri A, et al. Phase II study of capecitabine
(C) in combination with docetaxel (D) as neoadjuvant treatment in patients
with locally advanced breast cancer (IIIA and IIIB stage). J Clin Oncol
2004;22(July 15 Suppl.)(Abst 752).

[8] Lebowitz PF, Eng-Wong J, Swain SM, et al. A phase II trial of
neoadjuvant docetaxel and capecitabine for locally advanced breast cancer.

Clin Cancer Res 2004;10:6764-9.

[9] Tripathy D, Moisa C, Glück S. An open-label study of capecitabine and
docetaxel as neoadjuvant treatment for patients with recently diagnosed
HER2-negative breast cancer plus trastuzumab for HER2-positive breast cancer.
Eur J Cancer Suppl 2007;5:223 [Abst 2129].

[10] Rastogi, et al Preoperative chemotherapy: updates of National
Surgical Adjuvant Breast and Bowel Project Protocols B-18 B-27 J Clin Oncol.
2008 Feb 10;26(5):775-85

[11] Kamanger F et al Patterns of cancer incidence, mortality and
prevalence across five continents: defining priorities to reduce cancer
disparities in different geographic regions of the world. J Clin Oncol 2006;
24: 2137 – 2150

SOURCE Austrian Breast & Colorectal Cancer Study Group (ABCSG)

Source: newswire

comments powered by Disqus